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Background: Patients with either diabetes mellitus (DM) or metabolic syndrome (MS) are recognized as a high risk
group for cardiovascular disease (CVD). Several studies have demonstrated the clinical value of MS for predicting
additional CVD risk in the DM population, although the clinical significance remains debatable.
Methods: We used the Korea National Health and Nutrition Examination Survey (KNHANES) 2008, which is the
national representative database. We classified the KNHANES subjects based on MS and glucose tolerance status,
and compared clinical characteristics and future CVD risk among the subgroups.
Results: A total of 796 of the 4314 subjects were diagnosed with MS. Their clinical characteristics were significantly
different from patients without MS. Prevalence of DM was 9.5% in subjects with MS, but only 1.1% in subjects
without MS. In addition, there was no MS in 30.9% of total DM patients who were enrolled in this study. For the
normal and impaired fasting glucose subgroups, the prevalence of moderate (5–10%) and high (>10%) CVD risk
was significantly higher in patients with MS than in patients without MS (p < 0.001). However, in the DM subgroup,
even after multiple adjustments, there were no differences in clinical characteristics or in the prevalence of
moderate to high CVD risk according to MS status. That said, LDL cholesterol in the DM group without MS was
significantly higher than in the DM group with MS (p = 0.010).
Conclusions: The efficacy of MS as a screening tool for high CVD risk may be limited in DM patients, and
conventional risk factors such as LDL may be more important.
Keywords: Metabolic syndrome, Syndrome X, Cardiovascular disease, Framingham risk score, Diabetes mellitus, DM,
Dyslipidemia, Cholesterol, KNHANES, KoreaBackground
The term “metabolic syndrome” (MS) refers to a cluster
of metabolic risk factors that accelerate the development of
cardiovascular disease (CVD) [1]. Since Reaven described
“syndrome X” in 1988 [2], several expert groups have en-
deavored to identify diagnostic criteria that will more easily
identify patients with multiple risk factors for MS [3]. The
most widely recognized metabolic risk factors consist of* Correspondence: jtwoomd@khmc.or.kr
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unless otherwise stated.abdominal obesity; atherogenic dyslipidemia such as ele-
vated triglycerides (TG), apolipoprotein B-containing lipo-
proteins and low levels of high-density lipoprotein (HDL)
cholesterol; elevated blood pressure and glucose levels; and
prothrombotic and proinflammatory states [1,4,5]. The
mechanism of interaction among these metabolic risk
factors is not completely understood. However, these
factors appear to be associated with metabolic susceptibility
(e.g. insulin signaling defects, adipose tissue disorder,
mitochondrial dysfunction, endocrine dysfunction, ethnic
variations, aging, and drugs), and people who have meta-
bolic susceptibility usually manifest insulin resistance [6].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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in MS subjects is approximately double that of non-MS
subjects [4,7]. Therefore, aggressive interventional strat-
egies for CVD prevention should be initiated earlier in
MS subjects. However, there is still debate regarding the
value of MS as an additive risk factor for CVD in those
who have already been diagnosed with diabetes or have
a prediabetic conditions, such as impaired fasting glu-
cose (IFG) [8].
Our aim in this study was to investigate the association
of MS and future CVD risk based on glucose tolerance
status. Furthermore, we attempted to identify practical
methods for screening diabetes patients who are at high
risk for CVD using the nationally representative Korean
population data base, the Korea National Health and
Nutrition Examination Survey (KNHANES) of 2008.
Methods
KNHANES
KNHANES is a nationwide, population-based, and cross-
sectionally designed health survey conducted by the Korea
Centers for Disease Control and Prevention. After the first
KNHANES was conducted in 1998, the second, third,
and fourth surveys were conducted in 2001, 2005, and
2007–2009, respectively.
We utilized the KNHANES 2008 data in this
study. KNHANES 2008 was conducted from January to
December 2008. The subject population included all
households recorded in the 2005 Population and Housing
Census in Korea. Relevant households were randomly
selected through stratified and multistage probability
sampling. As rolling survey methods were used for sam-
pling, the sample for each year was a probability sample
representing all parts of the country.
Study subjects
Subjects aged 20 years and older were selected from the
KNHANES 2008 sample (n = 6,123). Of these 6,123
subjects, individuals taking medication for hypertension,
Diabetes Mellitus, or dyslipidemia (n = 1,303) were ex-
cluded to eliminate the potential effect of medication
on MS status, as were those with insufficient data to
diagnose MS (n =197). Subjects who had a chronic dis-
ease including any type of cancer, viral hepatitis carrier,
liver cirrhosis, current tuberculosis, chronic obstruct-
ive lung disease, renal failure, myocardial infarction,
angina or stroke were also excluded (n = 168). Subjects
lacking sufficient demographic data, including age,
sex, body mass index (BMI), physical activity, smoking
and drinking history, income level, education level,
residential district and occupation were also excluded
(n = 141). All subjects included in the study had blood
sample data. A total of 4,314 subjects were enrolled in
this study.Study Methods
The subjects were divided according to presence of MS
and glucose tolerance status. The Modified National
Cholesterol Education Program Adult Treatment Panel
III (NCEP-ATP III) criteria were adopted and MS was
diagnosed if a subject met three or more of the following
five factors: elevated waist circumference, TG ≥150 mg/dL,
HDL cholesterol <40 mg/dL in males and <50 mg/dL
in females, systolic blood pressure ≥130 mmHg and/or
diastolic ≥85 mmHg, and fasting glucose ≥100 mg/dL [9].
However, the criterion of waist circumference measurement
was selected based on the Korean Society for the Study of
Obesity criteria, as ≥90 cm in males and ≥85 cm in females
[10]. The ten-year CVD risk of subjects was also analyzed
by age, smoking status, total cholesterol, HDL cholesterol,
and systolic blood pressure using the Framingham risk
score [11,12]. Based on these risk criteria, subjects were
classified into low (<5%), moderate (5 to <10%) and
high-risk (≥10%) groups. Glucose tolerance status was
subdivided into normal fasting glucose (NFG), impaired
fasting glucose (IFG) and DM based on the fasting plasma
glucose concentration and the diagnostic criteria of the
American Diabetes Association [13]. Current smokers were
defined as those who had smoked more than five packs of
cigarettes during their lifetime and were smoking at the
time of the survey. All other subjects were defined as non-
smokers. Regular alcohol drinkers were those who currently
drank alcohol more than one glass per month regardless of
alcohol types, and all others were defined as non-drinkers.
The sixteen residential areas of the KNHANES were
classified into urban or rural areas. Household income
was divided into quartiles. Educational status was cate-
gorized as none, elementary school, middle school, high
school, or college or higher. Occupation was divided into
seven groups: group 1, managers, professionals, technicians
and associate professionals; group 2, clerical support
workers; group 3, service and sales workers; group 4,
skilled agricultural, forestry and fishery workers; group 5,
craft and related trades workers, plant and machine opera-
tors, and assemblers; group 6, elementary occupations;
group 7, housewife, student, and unemployed, based on
the 6th Korean Standard Classification of Occupations
from the Korean National Statistical Office, which was cre-
ated by following the International Standard Classification
of Occupations of the International Labor Organization
[14]. Physical activity of the subjects was categorized
according to their participation in recreational physical
activity during the week prior to the survey.
Samples from all subjects were collected after
a >8 hour period of fasting. Specimens were immedi-
ately transported to the central laboratory (NeoDIN
Medical Institute, Seoul, Korea) where they were ana-
lyzed within 24 hours. Biochemical measurements, in-
cluding total cholesterol, TG, HDL cholesterol, blood
Figure 1 Prevalence of glucose tolerance status by MS status.
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ferase (AST), alanine aminotransferase (ALT) and fast-
ing plasma glucose concentration were analyzed using
an automated analyzer (Hitachi Automatic Analyzer
7600; Tokyo, Japan) with enzymatic assays. HDL choles-
terol was evaluated using standard samples as equiva-
lents between the KNHANES central laboratory and the
U.S. Centers for Disease Control and Prevention to pro-
duce an accurate lipid profile. The differences between
the two laboratories were adjusted for by Passing–
Bablok regression [15]. LDL cholesterol levels were cal-
culated using the Friedewald equation [16]. Instead of
apolipoprotein, which is typically difficult to analyze in
a clinical setting, non-HDL cholesterol was analyzed as
a potential predictor of CVD risk in the presence of
high serum TG common in subjects with DM [17,18].
Non-HDL cholesterol was calculated as total cholesterol
concentration minus HDL cholesterol. The non-HDL/
HDL ratio was divided into tertiles to compare trends of
prevalence of IFG and DM in both MS and non-MS
subjects. Serum insulin concentration was measured
using a gamma counter (1470 Wizard, Perkin Elmer,
Turku, Finland) and an immunoradiometric assay (Bio-
source, Nivelles, Belgium). An updated homeostasis
model assessment (HOMA2) method was employed to
assess β-cell insulin secretion capacity (HOMA2%B)
and insulin sensitivity (HOMA2%S) in fasting plasma
glucose and fasting serum insulin [19,20]. The HOMA2
method, a computerized improvement on the standard
HOMA method, reflects a more accurate insulin secre-
tion capacity and insulin resistance than the previous
HOMA method [19,20].
Statistical analysis
All data are expressed as either numbers with propor-
tions for categorical variables or as means ± SD for nu-
merical variables. Student’s t-tests were used for the
comparison of continuous variables and Pearson's Chi-
square tests(χ2-test) were used for the comparison of
categorical variables of demographic and clinical char-
acteristics between MS subjects and non-MS subjects.
The study population was subdivided into NFG, IFG
and DM groups and the prevalence of MS based on glu-
cose tolerance status was analyzed by χ2-test. In those
subgroups, demographic and clinical characteristics and
CVD risk were analyzed according to the presence of
MS by independent sample t-test and χ2-test. Odds ra-
tios (ORs) and 95% confidence intervals (CIs) for the
prevalence of MS according to CVD risk were estimated
by logistic regression.
Statistical analyses were conducted using Predictive
Analytics Software (PASW; version 18.0) (SPSS, Inc.,
Chicago, IL, USA). P-values less than 0.05 were consid-
ered statistically significant.Ethics statement
Because this study analyzed publicly available data sets,
it was exempt from Institutional Review Board approval.
Results
Clinical characteristics
A total of 4,314 subjects were included for analysis in
this study. Subjects with MS and those who were classi-
fied as non-MS accounted for 18.5% (n = 796) and
81.5% (n = 3,518), respectively, of the total study popula-
tion (Additional file 1: Table S1). Mean age, BMI, per-
centage of males and current smokers were significantly
higher in the MS group than in the non-MS group (p <
0.001). When compared with MS subjects, non-MS sub-
jects tended to live in urban areas (p = 0.041), had a
higher household income (p < 0.001), and were more ed-
ucated (p < 0.001). Occupations were also significantly
different between the study groups (p = 0.002). Bio-
chemical parameters, including BUN (p < 0.001), cre-
atinine (p < 0.001), AST (p < 0.001), and ALT (p < 0.001)
were all significantly higher in MS subjects than in non-
MS subjects.
The prevalence of glucose tolerance status and MS
The prevalence of NFG, IFG and DM in the study sam-
ple were 78.6% (n = 3,392), 18.8% (n = 812), and 2.5%
(n = 110) respectively. However, there were significant
differences in the prevalence of each glucose tolerance
status according to MS status (Figure 1). Prevalence of
NFG, IFG, and DM in MS subjects was 40.3%, 50.1%,
and 9.5% respectively, whereas the prevalence was
87.3%, 11.7%, and 1.0%, respectively, in non-MS sub-
jects (p < 0.001). There was a significantly lower preva-
lence of DM in non-MS subjects, although non-MS
subjects comprised 30.9% of the DM subgroup.
Clinical characteristics according to glucose tolerance
status and MS
When comparing subjects by their glucose tolerance sta-
tus, there were significant differences in clinical variables
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and IFG subgroups (Table 1). However, there were no
significant differences except for the NCEP-ATP III
diagnostic criteria of MS between the MS subjects and
non-MS subjects in the DM subgroup. In fact, in the
DM subgroup, LDL cholesterol, which is an established
risk factor for cardiovascular disease, was significantly
higher in non-MS subjects than in MS subjects.
Risk of a cardiovascular event according to glucose
tolerance status and MS
Ten-year CVD event risk was estimated by the Framing-
ham risk score and compared according to glucose toler-
ance and MS status (Figure 2). Subjects diagnosed with
MS had a higher prevalence of moderate (5 to <10%)
and high (≥10%) CVD risk than non-MS subjects in the
NFG and IFG subgroups (p < 0.001). However, in the
DM subgroup, the presence of MS was not associated
with the prevalence of moderate or high CVD risk (p =
0.649). We also analyzed odds ratios for MS prevalence
in moderate or high CVD risk subjects by glucose toler-
ance status, and found that ORs for MS prevalence in
moderate or high CVD risk subjects in the DM sub-
group were not significant even after multiple adjust-
ments (Table 2).
Discussion
Metabolic syndrome and DM are the most well-known
CVD risk factors and are used as a measure of CVD risk
in many studies. The pathophysiology of MS is not com-
pletely understood, but since insulin resistance is known
to be a representative pathophysiological factor, many
studies have focused on the relationship between DM
and MS [21]. The prevalence of DM risk for patients
with MS (diagnosed per NCEP criteria) was 2.99 times
higher than patient without MS (95% CI 1.96–4.57) (P
for heterogeneity < 0.001) [22]. Approximately 60-70% of
DM patients have MS [23,24]. Previous research indi-
cates that DM and MS are independent CVD risk factors
but it is still unclear whether MS is useful as a predictor
of CVD risk in subjects with DM [24,25].
Our study classified the subjects into NFG, IFG and
DM subgroups according to glucose tolerance status and
analyzed the prevalence of MS and its relationship to
CVD risk using the Framingham risk score. CVD risk in
MS subjects was higher than in non-MS subjects in the
NFG and IFG subgroups, but there was no significant
difference in CVD risk between MS subjects and non-
MS subjects in the DM subgroup. This suggests that MS
is a useful CVD risk predictive factor in the NFG and
IFG subgroups, but not in the DM subgroup. On the
other hand, LDL cholesterol levels in non-MS subjects
in the DM subgroup were higher compared with MS
subjects in the DM subgroup. This is likely because DM,a strong CVD risk factor, already existed in the DM sub-
group, and the impact of DM was stronger than other
components included in the MS cluster.
The term metabolic syndrome refers to a cluster of
metabolic risk factors that accelerate the development of
cardiovascular disease, and there has been controversy
surrounding the establishment of MS diagnostic criteria
[3]. Some experts explain that the reason why DM is not
included in the NCEP-ATP III criteria (which include
BMI, waist circumference, high BP, high TG, low HDL,
and high fasting glucose) is because CVD risk associated
with MS preferentially increases in subjects with DM
[26]. This supports the conclusion of our study that DM
has a greater impact on CVD risk than other MS
components.
The American Heart Association designates Type 2
DM, together with Peripheral Arterial Disease (PAD)
and Carotid Artery Disease (CAD), as “Coronary Heart
Disease (CHD) risk equivalents” [5]. In DM patients,
hyperglycemia works synergistically with other CVD risk
factors such as hypertension, dyslipidemia, obesity, re-
duced physical activity, and cigarette smoking to in-
crease CVD morbidity and mortality. Due to insulin
resistance, plasminogen activator inhibitors and fibrino-
gen increase and the coagulation process is reinforced so
that fibrinolysis is hindered. In addition, DM is related
to endothelial, vascular, smooth muscle, and platelet dys-
function [27]. A recent study measured circulating endo-
thelial progenitor cells (EPCs) in CHD and CHD risk
equivalent (PAD, CAD and Type 2 diabetes mellitus)
groups [28]. EPCs play an important role in neovasculo-
genesis, vascular repair and atherogenic processes. There
were more EPCs in subjects with DM than in other dis-
ease groups. These results are another evidence that DM
has a strong influence on CVD prevalence. Therefore,
independent CVD risk factors such as LDL cholesterol,
age, gender, cigarette smoking and family history or pa-
rameters such as hs-CRP, CD40L, MCP-1, ICAM-1,
VCAM-1, and p-selectin might be helpful in determin-
ing CVD risks in individuals with DM [29]. New diag-
nostic tools should be developed to help correctly
predict CVD.
Recently Li et al. studied the relationship between the
prevalence of MS and non-embolic ischemic stroke ac-
cording to glucose tolerance status [30]. The results
showed that MS prevalence was higher in the stroke
group than in the control group. Subjects were then
classified according to glucose tolerance status (NGT,
IFG or DM) and a multiple logistic regression analysis
was performed. This analysis showed that the ORs of is-
chemic stroke in the MS with DM, MS with IFG and
MS with NGT groups were all high (5.70, 2.24 and 2.19,
respectively) (p < 0.05). Among them, the odds ratio was
the highest in the MS with DM group. Accordingly, they
Table 1 Demographic and clinical characteristics of the subjects by glucose tolerance and MS status
NFG IFG DM
MS (−) n =
3,071
MS (+) n =
321
p MS (−) n =
413
MS (+) n =
399
p MS (−) n =
34
MS (+) n =
76
p
Age (yrs) 42.1 ± 14.6 50.5 ± 15.5 <0.001 49.4 ± 14.4 50.9 ± 13.0 0.129 51.6 ± 12.7 50.0 ± 13.2 0.536
Sex (M/F, n) 1188/1883 159/162 <0.001 213/200 226/173 0.147 23/11 42/34 0.222
BMI (kg/m2) 22.6 ± 2.9 26.3 ± 3.1 <0.001 23.1 ± 2.9 25.9 ± 3.2 <0.001 23.5 ± 3.3 26.1 ± 3.7 0.001
Smoking (n,%)
No smoker 2353 (76.6) 241 (75.1) 0.535 316 (76.5) 270 (67.7) 0.005 24 (70.6) 50 (65.8) 0.620
Current smoker 718 (23.4) 80 (24.9) 97 (23.5) 129 (32.3) 10 (29.4) 26 (34.2)
Alcohol (n,%)
No drinker 1,292 (42.1) 158 (49.2) 0.014 161 (39.0) 153 (38.3) 0.852 13 (38.2) 29 (38.2) 0.994
Regular drinker 1,779 (57.9) 163 (50.8) 252 (61.0) 246 (61.7) 21 (61.8) 47(61.8)
Locationa (n,%)
Urban area 2,007 (65.4) 189 (58.9) 0.021 263 (63.7) 254 (63.7) 0.995 22 (64.7) 45 (59.2) 0.585
Rural area 1,064 (34.6) 132 (41.1) 150 (36.3) 145 (36.3) 12 (35.3) 31 (40.8)
Household incomeb (n,%)
1st quartile (lowest) 425 (13.8) 78 (24.3) <0.001 69 (16.7) 64 (16.0) 0.672 9 (26.5) 18 (23.7) 0.522
2nd quartile 773 (25.2) 77 (24.0) 117 (28.3) 100 (25.1) 7 (20.6) 21 (27.6)
3rd quartile 900 (29.3) 82 (25.5) 117 (28.3) 125 (31.3) 6 (17.6) 19 (25.0)




499 (16.2) 105 (32.7) <0.001 102 (24.7) 127 (31.8) 0.109 13 (38.2) 25 (32.9) 0.686
Middle school 281 (9.2) 38 (11.8) 50 (12.1) 52 (13.0) 1 (2.9) 6 (7.9)
High school 1,216 (39.6) 102 (31.8) 163 (39.5) 136 (34.1) 9 (26.5) 24 (31.6)
College or higher 1,075 (35.0) 76 (23.7) 98 (23.7) 84 (21.1) 11 (32.4) 21 (27.6)
Occupationc (n,%)
Group 1 429 (14.0) 40 (12.5) 0.214 42 (10.2) 44 (11.0) 0.783 3 (8.8) 11 (14.5) 0.577
Group 2 269 (8.8) 25 (7.8) 29 (7.0) 29 (7.3) 2 (5.9) 5 (6.6)
Group 3 398 (13.0) 57 (17.8) 52 (12.6) 52 (13.0) 6 (17.6) 14 (18.4)
Group 4 266 (8.7) 21 (6.5) 43 (10.4) 50 (12.5) 6 (17.6) 9 (11.8)
Group 5 295 (9.6) 36 (11.2) 62 (15.0) 68 (17.0) 8 (23.5) 11 (14.5)
Group 6 259 (8.4) 27 (8.4) 53 (12.8) 42 (10.5) 4 (11.8) 5 (6.6)
Group 7 1,155 (37.6) 115 (35.8) 132 (32.0) 114 (28.6) 5 (14.7) 21 (27.6)
Physical activityd (n,%)
None 1,270(41.4) 153 (47.7) 0.148 172 (41.6) 166 (41.6) 0.098 12 (35.3) 31 (40.8) 0.771
Mild 959 (31.2) 92 (28.7) 117 (28.3) 105 (26.3) 11 (32.4) 19 (25.0)
Moderate 297 (9.7) 30 (9.3) 37 (9.0) 50 (12.5) 6 (17.6) 11 (14.5)
Vigorous 545 (17.7) 46 (14.3) 87 (21.1) 78 (19.5) 5 (14.7) 15 (19.7)
Total cholesterol (mg/dL) 180.9 ± 32.8 202.8 ± 33.9 <0.001 193.7 ± 33.6 201.2 ± 35.8 0.002 206.8 ± 43.1 204.1 ± 35.2 0.732
Triglycerides (mg/dL) 103.9 ± 77.6 251.3 ± 192.9 <0.001 105.7 ± 62.0 217.8 ± 156.2 <0.001 114.1 ± 64.3 256.5 ± 177.5 <0.001
HDL cholesterol (mg/dL) 50.2 ± 10.6 38.9 ± 5.8 <0.001 51.8 ± 10.0 41.4 ± 8.6 <0.001 51.8 ± 10.0 40.8 ± 7.6 <0.001
LDL cholesterol (mg/dL) 110.0 ± 29.9 113.6 ± 44.2 0.145 120.7 ± 31.3 116.2 ± 40.3 0.080 132.2 ± 34.4 112.1 ± 38.5 0.010
Non-HDL cholesterol (mg/dL) 130.7 ± 32.6 163.9 ± 33.0 <0.001 141.8 ± 32.6 159.8 ± 34.4 <0.001 155.0 ± 40.7 163.4 ± 34.4 0.269
Non-HDL/HDL ratio 2.7 ± 1.0 4.3 ± 1.0 <0.001 2.8 ± 0.8 4.0 ± 1.1 <0.001 3.1 ± 0.9 4.1 ± 1.1 <0.001
BUN (mg/dL) 13.7 ± 3.9 14.4 ± 3.9 0.003 15.2 ± 4.6 14.8 ± 3.8 0.143 16.3 ± 4.2 14.9 ± 4.2 0.092
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Table 1 Demographic and clinical characteristics of the subjects by glucose tolerance and MS status (Continued)
Creatinine (mg/dL) 0.89 ± 0.18 0.95 ± 0.21 <0.001 0.92 ± 0.19 0.93 ± 0.20 0.394 0.89 ± 0.18 0.93 ± 0.24 0.440
AST (IU/L) 20.2 ± 13.1 23.4 ± 11.4 <0.001 22.8 ± 25.2 24.4 ± 11.2 0.234 26.2 ± 21.4 31.7 ± 34.3 0.394
ALT (IU/L) 18.6 ± 14.8 27.4 ± 21.4 <0.001 22.5 ± 43.3 28.7 ± 18.9 0.008 25.9 ± 16.9 34.1 ± 26.7 0.055
Fasting plasma glucose (mg/
dL)
88.7 ± 6.0 91.6 ± 5.1 <0.001 105.9 ± 5.9 107.3 ± 6.5 0.001 160.8 ± 43.4 167.0 ± 45.2 0.505
Fasting serum insulin 8.50 ± 3.28 11.53 ± 7.42 <0.001 9.52 ± 5.13 11.99 ± 7.24 <0.001 11.80 ± 9.01 12.92 ± 8.52 0.533
HOMA2%B (%) 104.4 ± 28.7 118.6 ± 40.5 <0.001 78.2 ± 25.5 88.7 ± 31.7 <0.001 45.0 ± 26.9 47.8 ± 31.0 0.641
HOMA2%S (%) 102.7 ± 35.2 79.2 ± 28.7 <0.001 91.9 ± 34.2 77.0 ± 32.7 <0.001 84.2 ± 43.6 68.9 ± 34.0 0.076
by independent t-test or chi-square test, mean ± S.D. or n (%).
aThe 16 residential areas of the KNHANES were classified into two groups: urban areas, including metropolitan cities such as Seoul, Busan, Daegu, Incheon,
Gwangju, Daejeon, and Ulsan, as well as metropolitan areas such as Gyeonggi province; rural areas, comprising Gangwon, Chungbuk, Chungnam, Jeonnam,
Jeonbuk, Gyeongbuk, Gyeongnam, and Jeju provinces. bHousehold income was assigned to a category according to the following quartiles: 1st quartile (<bottom
25%), 2nd quartile (25-49%), 3rd quartile (50-75%) and 4th quartile (>top 25%). cOccupation group referred to the KSCO-6 classification. Group 1 indicates managers,
professionals, technicians and associate professionals; group 2, clerical support workers; group 3, service and sales workers; group 4, skilled agricultural, forestry and
fishery workers; group 5, craft and related trades workers, plant and machine operators, and assemblers; group 6, elementary occupations; group 7, housewife,
student, and unemployed. dPhysical activity of the subjects was categorized according to their participation in recreational physical activity during the week
prior to the survey: none, no or minimal activity; mild, >30 minutes of walking more than 5 days per week; moderate, >30 minutes of physical activity in which
the subject was tired or breathing slightly hard compared to normal more than 5 days per week; vigorous, >20 min of vigorous physical activity in which the
subject was exhausted or breathing hard compared to normal more than 3 days per week. MS indicates Metabolic syndrome; NFG, normal fasting glucose; IFG,
impaired fasting glucose; DM, diabetes mellitus; BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; BUN, blood urea nitrogen;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; FPG, fasting plasma glucose; HOMA2%B, updated homeostasis model assessment for β-cell
insulin secretion; HOMA2%S, updated homeostasis model assessment for insulin sensitivity.
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cially in hyperglycemic patients with DM. This contra-
dicts the findings of our study, but this may be due to
the fact that they measured blood glucose when a stroke
was occurring, and included only acute cerebral stroke
patients who visited a university medical center emer-
gency room within 2 hours of the onset of symptoms
[30].
Kim et al. studied the association between inflamma-
tory markers, adipokines (hs-CRP, IL-6, resistin, and adi-
ponectin) and MS score. In addition, they explored
whether or not MS score is useful in predicting the risk
of coronary artery disease in patients with chest pain
who received a coronary angiography, according to DM
status [31]. Their study findings were similar to ours.
MS score was useful in predicting CAD risk in non-DMFigure 2 Ten-year cardiovascular disease risk by glucose tolerance anpatients, and an increased MS score was associated with
increased IL-6 and decreased adiponectin. However, MS
score was not useful for predicting CAD risk in DM pa-
tients, nor there was any consistent relationship between
MS scores and bioparameters in DM patients. Their
study did not completely exclude medication effects
such as the effect of anti-diabetic agents, and their work
was conducted on patients who likely had CAD and
were treated with coronary angiography. On the other
hand, our study avoided selection bias and obtained
more objective results because it excluded medication
effects, used the Framingham risk score as a CVD risk
prediction method, and used KNHANES 2008 data to
create a large-scale subject group.
This study has several limitations. The first issue is
that it is unclear if the Framingham risk score will bed MS status estimated by Framingham risk score.
Table 2 Odds ratio (ORs) and 95% confidence interval (CI) for prevalence of MS in moderate of high CVD risk
subgroup by glucose tolerance status
Prevalence of MS (n,%) Adjusted ORs (95% CI)
Total subjects
Low CVD risk 411 (13.1) Referent
Moderate CVD risk 154 (31.8) 3.009* (2.405-3.765)
High risk 219 (34.5) 3.502* (2.856-4.295)
NGT subjects
Low CVD risk 172 (6.6) Referent
Moderate CVD risk 61 (19.5) 3.549* (2.544-4.952)
High risk 82 (19.9) 3.735* (2.750-5.072)
IFG subjects
Low CVD risk 207 (44.7) Referent
Moderate CVD risk 69 (49.3) 1.179 (0.802-1.734)
High risk 119 (61.7) 1.980* (1.390-2.821)
DM subjects
Low CVD risk 32 (66.7) Referent
Moderate CVD risk 24 (75.0) 2.367 (0.754-7.437)
High risk 74 (68.5) 1.159 (0.389-3.451)
*p < 0.01. Adjusted for location, household income, and occupation.
MS indicates metabolic syndrome, CVD cardiovascular disease.
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lence in the future. In fact, some researchers believe
that the Framingham risk score underestimates CVD
risk in specific age and gender groups [32,33]. In
addition, more precise methods are available to meas-
ure CVD risk, such as the coronary artery calcium
score by computed tomography and carotid intima-
media thickness by ultrasonography. However, the Fra-
mingham risk score is still recognized as a reliable pre-
dictor of CVD risk and continues to be used frequently
in clinical settings [34]. Carotid intima-media thickness
by ultrasonography or coronary artery calcium score by
computed tomography (CT) for the purpose of screen-
ing is costly, and also may result in unnecessary expos-
ure to contrast media. Another limitation of this study
is the cross-sectional design. Therefore, the results of
this study cannot provide long-term information about
the relationship between MS and CVD risk. Thus, fu-
ture studies should be long-term and retrospective or
prospective in nature. Finally, this study is not widely
applicable because it was conducted on Korean subjects
only. There are many genetic and lifestyle differences
between ethnicities that can greatly impact MS compo-
nents. Therefore, future studies of replication should
include individuals of various ethnic backgrounds.
However, the results of this study are more objective
than similarly scaled studies due to the use of national
representative epidemiological data, KNHANES, which
is collected through strict quality control. Using the
KNHANES 2008 database made it possible to gathersocioeconomic variables and control and adjust for the
effect of these variables on study results. Hence, the re-
sults of this study are relatively accurate and detailed
analyses were possible.
In addition, our study segmented groups according to
glucose tolerance status. This is important because it
was possible to independently classify prediabetes pa-
tients into the NGT, IGT and DM group according to
glucose tolerance status rather than simply creating a
DM and a non-DM group. Also, considering that high
fasting glucose is an MS component, it is impossible to
completely exclude the influence of hyperglycemia on
CVD risk in the MS group. However, we could control
the influence of hyperglycemia by dividing the MS group
according to glucose tolerance status. And we focused
on other MS components except high fasting glucose.
In conclusion, MS is not a useful tool for screening
CVD risk in DM patients, but may be applicable in NFG
or IFG patients. Currently, stress tests such as exercise
or adenosine stress SPECT radionuclide myocardial per-
fusion imaging (rMPI), dobutamine-atropine stress echo-
cardiography and coronary angiography, noninvasive CT
coronary angiogram or cardiac magnetic resonance im-
aging (MRI) techniques have used for screening of car-
diovascular disease in DM patients. However, these tests
are too invasive, expensive and not accessible. Also, pa-
tients could be exposed to radiation and contrast media.
Instead, conventional risk factors such as age, gender,
cigarette smoking, family history, LDL cholesterol, and
inflammation markers may be more important when
Rhee et al. Diabetology & Metabolic Syndrome 2014, 6:98 Page 8 of 9
http://www.dmsjournal.com/content/6/1/98predicting CVD risk in DM patients. Therefore, MS can
be a good tool for non-DM patients, while it is necessary
to further study and develop new tools and criteria for
risk prediction in DM patients.
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